Log in

Key Steps Toward a Promotional Communications Strategy: Collaboration Best Practices for Teams Creating Promotional Materials and Regulatory Colleagues

  • Review
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

A promotional communications strategy is considered early in prescription medical product development by commercial disciplines (e.g., commercial/marketing) and informs promotional materials to key stakeholders such as healthcare providers and patients. Health economics and outcomes research (HEOR) is a scientific discipline that is also responsible for the generation of promotional materials to other key stakeholders such as payors. The overarching promotional strategy benefits from consistent partnerships with regulatory affairs colleagues, culminating in cost savings and patient-centric promotional materials. Yet there is a paucity of published content that details effective collaboration between promotional teams and regulatory colleagues prior to medical/legal/regulatory (MLR) review. The following review aims to showcase such organizational innovation from the perspective of teams develo** promotional materials (i.e., commercial and HEOR). Behind-the-scenes marketing activities are described in relation to the following key steps that build the strategy’s foundation: insight gathering from key stakeholders; sub-strategy development; tactic identification; and promotional message development. Integration of regulatory colleagues with teams develo** promotional materials is imperative to accomplish these key steps prior to any MLR review. Finally, four themes in best practices for collaboration with regulatory colleagues are shared from the perspective of commercial disciplines and HEOR, alongside a real-world example for each: (1) Alignment of Strategies; (2) Shared Process & Tools; (3) Creative Problem-Solving; and (4) Culture of Connecting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Wouters O, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. J Am Med Assoc. 2020;323(9):844–53. https://doi.org/10.1001/jama.2020.1166.

    Article  Google Scholar 

  2. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997–2016. J Am Med Assoc. 2019;321(1):80–96. https://doi.org/10.1001/jama.2018.19320.

    Article  Google Scholar 

  3. FDA. Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers: Final Guidance for Industry and Review Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-and-device-manufacturer-communications-payors-formulary-committees-and-similar-entities.

  4. Cook PB, Purcell T, Subramanyam J, Golan E, Phinney T, Totosy de Zepetnek J. Regulatory Insights Throughout the Commercialization Realm and Product Lifecycle. Virtual Conference: RAPS Convergence; 2020.

  5. Mantus DS. The practice of regulatory affairs. In: Mantus D, Pisano DJ, editors. FDA regulatory affairs. 3rd ed. New York: Taylor and Francis Group, LLC; 2014. p. 309–26.

    Chapter  Google Scholar 

  6. Karstrom K. Collaboration to win with regulatory teams. Motionstrand Website. https://www.motionstrand.com/news/collaborating-win-regulatory-teams.

  7. Robinson R. Collaboration within the commercialization process. PharmaVOICE. https://www.pharmavoice.com/article/2017-4-commercialization/.

  8. Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving patient involvement in medicines research and development: a practical roadmap. Ther Innov Regul Sci. 2017;51(5):612–9. https://doi.org/10.1177/2168479017706405.

    Article  PubMed  Google Scholar 

  9. Mezher M. Researchers link target product profiles to shorter review times. Regulatory Affairs Professional Society (RAPS). https://www.raps.org/regulatory-focus™/news-articles/2017/4/researchers-link-target-product-profiles-to-shorter-review-times.

  10. Dillon C, Knapp J, Stinson M. An evolved approach to advisory boards in rare disease drug development: 5-step model to finding and engaging patient advisors. J Patient Exp. 2020;7(6):978–81. https://doi.org/10.1177/2374373520948441.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Aikin KJ, Sullivan HW, Betts KR. Disease information in direct-to-consumer prescription drug print ads. J Health Commun. 2016;21(2):228–39. https://doi.org/10.1080/10810730.2015.1058440.

    Article  PubMed  Google Scholar 

  12. Raber-Johnson ML, Gallwitz WE, Sullivan EJ, Storer P. Innovation in clinical trial design and product promotion: evolving the patient perspective with regulatory and technological advances. Ther Innov Regul Sci. 2020;54(3):519–27. https://doi.org/10.1007/s43441-019-00083-5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mary L. Raber-Johnson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raber-Johnson, M.L., Stinson, M., Dillon, C. et al. Key Steps Toward a Promotional Communications Strategy: Collaboration Best Practices for Teams Creating Promotional Materials and Regulatory Colleagues. Ther Innov Regul Sci 55, 696–704 (2021). https://doi.org/10.1007/s43441-021-00272-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43441-021-00272-1

Navigation